Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-06, Stock:NVO, The news for the past five days is as follows:
2019-01-30: NEWS1: House Democratic leaders probe 3 major drugmakers on insulin prices.NEWS2: Biotech Stocks Facing FDA Decision In February.NEWS3: Biotech Stocks Facing FDA Decision In February.
2019-01-31: NEWS1: Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?.NEWS2: Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?.NEWS3: Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?.
2019-02-01: NEWS1: Health Care Sector Update for 02/01/2019: TTNP,ZBH,NVO,CTIC.NEWS2: Health Care Sector Update for 02/01/2019: TTNP,ZBH,NVO,CTIC.NEWS3: Health Care Sector Update for 02/01/2019: ZBH,NVO,CTIC.NEWS4: Health Care Sector Update for 02/01/2019: ZBH,NVO,CTIC.NEWS5: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates.NEWS6: [$$] Danish Drugmaker Expects Higher Working Capital as Brexit Looms.NEWS7: Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat.NEWS8: European ADRs Move Lower in Friday Trading.NEWS9: European ADRs Move Lower in Friday Trading.NEWS10: Novo Nordisk CEO backs ending drug industry rebate system.NEWS11: Novo Nordisk: 4Q Earnings Snapshot.NEWS12: Novo Nordisk's new diabetes drug, outlook lift shares.NEWS13: Novo Nordisk's new diabetes drug, outlook lift shares.NEWS14: Novo Nordisk CEO Applauds Trump Plan to Limit Rebates.NEWS15: [$$] Novo Nordisk Net Profit Rise Misses Expectations.NEWS16: Novo Nordisk 2018 Net Profit Rises.NEWS17: Novo Nordisk 2018 Net Profit Rises.
2019-02-04: NEWS1: 5 of the Best Biotech Stocks to Buy Now.NEWS2: 5 of the Best Biotech Stocks to Buy Now.
2019-02-05: NEWS1: Novo Nordisk Is on the Upswing -- for Now.NEWS2: Sanofi's Myeloma Candidate Meets Goal in Phase III Study.NEWS3: Sanofi's Myeloma Candidate Meets Goal in Phase III Study.NEWS4: Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer.NEWS5: Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer.NEWS6: Sanofi's Myeloma Candidate Meets Goal in Phase III Study.NEWS7: Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer.

Answer: Decrease